Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework
Digital Biomarkers · 30.09.2022 · 6 (3) · 107-116
DOI: 10.1159/000526471 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digital Biomarkers, online erschienen am 30.09.2022. Verfasst von Johannes Tröger und 11 weiteren Autor:innen. Beteiligte Einrichtung: ki elements, Saarbrücken, Germany. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Progressive cognitive decline is the cardinal behavioral symptom in most dementia-causing diseases such as Alzheimer’s disease. While most well-established measures for cognition might not fit tomorrow’s decentralized remote clinical trials, digital cognitive assessments will gain importance. We present the evaluation of a novel digital speech biomarker for cognition (SB-C) following the Digital Medicine Society’s V3 framework: verification, analytical validation, and clinical validation.
Methods
Evaluation was done in two independent clinical samples: the Dutch DeepSpA (N = 69 subjective cognitive impairment [SCI], N = 52 mild cognitive impairment [MCI], and N = 13 dementia) and the Scottish SPeAk datasets (N = 25, healthy controls). For validation, two anchor scores were used: the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating (CDR) scale.
Results
Verification: The SB-C could be reliably extracted for both languages using an automatic speech processing pipeline. Analytical Validation: In both languages, the SB-C was strongly correlated with MMSE scores. Clinical Validation: The SB-C significantly differed between clinical groups (including MCI and dementia), was strongly correlated with the CDR, and could track the clinically meaningful decline.
Conclusion
Our results suggest that the ki:e SB-C is an objective, scalable, and reliable indicator of cognitive decline, fit for purpose as a remote assessment in clinical early dementia trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ki elements, Saarbrücken, Germany.
- Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
- Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.
Zitieren
APA
Tröger, J., Baykara, E., Zhao, J., Ter Huurne, D., Possemis, N., Mallick, E., Schäfer, S., Schwed, L., Mina, M., Linz, N., Ramakers, I., & Ritchie, C. (2022). Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework. Digital Biomarkers, 6(3), 107-116. https://doi.org/10.1159/000526471
Vancouver
Tröger J, Baykara E, Zhao J, Ter Huurne D, Possemis N, Mallick E, et al. Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework. Digital Biomarkers. 2022;6(3):107-116. doi:10.1159/000526471
BibTeX
@article{Trger2022,
author = {Tröger, Johannes and Baykara, Ebru and Zhao, Jian and Ter Huurne, Daphne and Possemis, Nina and Mallick, Elisa and Schäfer, Simona and Schwed, Louisa and Mina, Mario and Linz, Nicklas and Ramakers, Inez and Ritchie, Craig},
title = {Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework},
journal = {Digital Biomarkers},
year = {2022},
volume = {6},
number = {3},
pages = {107--116},
doi = {10.1159/000526471}
}
EUVIMED